Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention by Katherine Karakasis et al.
May 2016 | Volume 6 | Article 1191
Review
published: 11 May 2016
doi: 10.3389/fonc.2016.00119
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Sarah M. Temkin, 
National Cancer Institute, USA
Reviewed by: 
Tamara Louise Kalir, 
The Mount Sinai School 
of Medicine, USA 
Paola Gehrig, 
University of North Carolina, USA
*Correspondence:
Stephanie Lheureux  
stephanie.lheureux@uhn.ca
Specialty section: 
This article was submitted 
to Women's Cancer, 
a section of the journal 
Frontiers in Oncology
Received: 26 February 2016
Accepted: 28 April 2016
Published: 11 May 2016
Citation: 
Karakasis K, Burnier JV, Bowering V, 
Oza AM and Lheureux S (2016) 
Ovarian Cancer and BRCA1/2 
Testing: Opportunities to Improve 
Clinical Care and Disease Prevention. 
Front. Oncol. 6:119. 
doi: 10.3389/fonc.2016.00119
Ovarian Cancer and BRCA1/2 
Testing: Opportunities to improve 
Clinical Care and Disease Prevention
Katherine Karakasis, Julia V. Burnier, Valerie Bowering, Amit M. Oza and  
Stephanie Lheureux*
Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of 
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Without prevention or screening options available, ovarian cancer is the most lethal 
malignancy of the female reproductive tract. High-grade serous ovarian cancer (HGSOC) 
is the most common histologic subtype, and the role of germline BRCA1/2 mutation in 
predisposition and prognosis is established. Given the targeted treatment opportunities 
with PARP inhibitors, a predictive role for BRCA1/2 mutation has emerged. Despite 
recommendations to provide BRCA1/2 testing to all women with histologically confirmed 
HGSOC, uniform implementation remains challenging. The opportunity to review and 
revise genetic screening and testing practices will identify opportunities, where universal 
adoption of BRCA1/2 mutation testing will impact and improve treatment of women 
with ovarian cancer. Improving education and awareness of genetic testing for women 
with cancer, as well as the broader general community, will help focus much-needed 
attention on opportunities to advance prevention and screening programs in ovarian 
cancer. This is imperative not only for women with cancer and those at risk of developing 
cancer but also for their first-degree relatives. In addition, BRCA1/2 testing may have 
direct implications for patients with other types of cancers, many of which are now being 
found to have BRCA1/2 involvement.
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iNTRODUCTiON
Over the last four decades, there has been modest progress in the 5-year overall survival rates of 
women diagnosed with ovarian cancer, despite enhanced surgical efforts and introduction of doublet 
platinum/taxane chemotherapy. Worldwide, newly diagnosed cases of ovarian cancer have reached 
239,000, positioning this malignancy as the seventh most common cancer in all women, with the 
highest incidence in Europe and North America (1). Typically diagnosed at an advanced stage (III/
IV), high mortality rates for ovarian cancer continue to persist with almost 152,000 deaths per year 
(Figure 1) (2).
The lifetime risk of spontaneously developing and dying from ovarian cancer are 1.39 and 1.04%, 
respectively; however, the incidence of developing ovarian cancer significantly increases in carriers 
of germline mutations, mainly with either the breast cancer gene 1 (BRCA1) or 2 (BRCA2) genes. 
The lifetime risk of developing ovarian cancer is 40–60 and 11–27% for BRCA1 and BRCA2 muta-
tion carriers, respectively (3). These particular mutations are implicated in 10–15% of all ovarian 
FiGURe 1 | Ovarian cancer incidence and mortality rates worldwide (ASR) based on GloboCan data (1).
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cancer cases and almost 20% of high-grade serous histology 
[high-grade serous ovarian cancer (HGSOC)] (4), including 
in women without a family history of breast or ovarian cancer. 
Approximately, one-third of patients with hereditary ovarian can-
cer have no close relatives with cancer (3). Family history-based 
testing for BRCA1/2 germline mutations has been shown to miss 
a significant proportion of women at risk for developing cancer 
(5), perhaps as a result of incomplete or incorrect family history 
reporting (6, 7) or potentially due to a lack of updating new family 
history information as it becomes available (8).
At present, a variety of selection criteria are used to determine 
the eligibility for BRCA1/2 testing, including family history, age 
at onset, tumor clinicopathological features, and computational 
risk prediction models (BRCAPRO, BOADICEA, Myriad, and 
Manchester scoring system) (9). The clinical criteria for risk 
assessment, genetic counseling, and genetic testing for BRCA-
related cancers in women are based on personal and family 
history factors that may contribute to the disease (10) and are 
related to the likelihood of testing positive above a common 
testing threshold of 10% (11). These models often underestimate 
the probability of finding a mutation (12–14). It has been shown 
that the current family history approach does not identify 60% of 
Ashkenazi Jewish BRCA mutation carriers (15), thus creating a 
critical gap in practice that affects clinical treatment strategy and 
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possibly patient outcome. As such, in light of advances in our 
understanding of BRCA-related breast and ovarian cancers – and 
the opportunity to directly impact therapeutic decision-making 
in these women  –  the recommendations to include universal 
germline BRCA1/2 testing to all women diagnosed with non-
mucinous ovarian carcinoma (4) and women with triple-negative 
breast cancer (16) are growing in strength (17–19). Using next 
generation sequencing for 21 tumor suppressor genes of 360 sub-
jects, ~24% carried germline loss-of-function mutations: 18% in 
BRCA1 or BRCA2 and 6% in BARD1, BRIP1, CHEK2, MRE11A, 
MSH6, NBN, PALB2, RAD50, RAD51C, or TP53 (20). The study 
also showed that 31% of women with an inherited mutation had 
no prior personal history of cancer or family history of breast 
or ovarian cancers (20). The National Comprehensive Cancer 
Network (NCCN) and Society of Gynecologic Oncology (SGO) 
guidelines suggest universal genetic counseling and testing of 
all women with ovarian cancer, including fallopian tube and 
peritoneal cancer (17, 19). Given the rate of BRCA1/2 mutation 
in HGSOC, germline BRCA1/2 testing is especially warranted 
in practice for this histology subtype. An immediate improve-
ment to treatment opportunities would be to offer systematically 
genetic testing for BRCA1/2 mutation to all HGSOC, although 
it has been reported that 20% of women with ovarian cancer in 
community hospital settings were referred for genetic testing 
(21). While this was shown to be improved in academic centers, 
referral for germline BRCA1/2 testing was not systematic and 
did not reach the majority of patients (22). In clinical practice, 
there is a critical gap between the women eligible for BRCA1/2 
counseling and those receiving testing (23, 24). With the recent 
approval of olaparib, a PARP inhibitor, it is likely that referral for 
genetic testing of BRCA1/2 status will improve.
KNOwLeDGe OF BRCA1/2 MUTATiON 
STATUS iMPACTS CLiNiCAL CARe OF 
wOMeN wiTH OvARiAN CANCeR
Knowledge of BRCA1/2 status should be part of the standard of 
care at least for patients diagnosed with HGSOC. Indeed, there 
is a large body of evidence indicating benefits of targeting path-
ways involved in maintaining DNA integrity, including BRCA1 
and BRCA2 signaling (25). Harboring a germline BRCA1/2 
mutation is described as predictive of platinum sensitivity 
(26). Moreover, based on the synthetic lethality concept  –  the 
simultaneous promotion of DNA double-strand breaks (DSBs) 
and hindrance of DSB repair by inhibition of PARP protein 
expression (27, 28)  –  PARP inhibitors have been developed. 
This effect was shown clinically in the pivotal international, 
multicenter, randomized, phase II study that evaluated olaparib 
(a PARP inhibitor) as maintenance treatment in women with 
HGSOC who had responded to platinum-based chemotherapy 
(29). The preplanned retrospective analysis of outcomes by 
BRCA1/2 status in this study demonstrated that BRCA-mutated 
patients had better progression-free survival (PFS) with olaparib 
maintenance compared to those receiving placebo (11·2 versus 
4·3 months; HR 0·18; p < 0·0001) (30). The PFS benefit was still 
observed when somatic BRCA-mutated patients were included in 
the analysis. Additional evidence supporting the role of olaparib 
as  maintenance therapy was reported from an international, mul-
ticenter, randomized, open-label study in women with platinum-
sensitive relapsed HGSOC (NCT01081951) (31). In this phase 
II, olaparib was given with carboplatin/paclitaxel chemotherapy 
and continued as maintenance monotherapy. Overall, study 
findings show a significant PFS improvement when compared 
to chemotherapy alone (12.2 and 9.6 median PFS, respectively; 
HR 0.51; 95% CI 0.34–0.77; p = 0.0012). A greater benefit was 
detected in patients with a BRCA1/2 mutation (PFS HR 0.21; 
95% CI 0.08–0.55; p = 0.015) than in those without a BRCA1/2 
mutation. Further, study analysis revealed strong evidence 
that olaparib maintenance is most likely a key contributor to 
the improvement in PFS in this patient population (31). There 
are numerous ongoing PARP inhibitor studies investigating 
women with BRCA1/2 mutations as well as mutations in other 
homologous recombination-deficient (HRD) genes, as data has 
shown HRD genes to exhibit BRCA-like behavior (32). To date, 
the use of olaparib maintenance has been approved in Europe 
after response to platinum-based chemotherapy in women with 
platinum-sensitive HGSOC who harbor a germline or somatic 
BRCA1/2 mutation (30) and in US, as single agent therapy after 
three lines of chemotherapy in patients with germline BRCA1/2 
mutation HGSOC (33). Taken together, germline and somatic 
testing for BRCA1/2 provides important information for patients 
with ovarian cancer and this knowledge can directly impact clini-
cal care.
KNOwLeDGe OF GeRMLiNe BRCA1/2 
MUTATiON STATUS iMPACTS OvARiAN 
CANCeR PReveNTiON
Germline BRCA1/2 status is not only relevant to women with 
ovarian cancer but also to women without cancer, who may be 
at an increased risk of developing the disease and could therefore 
benefit from prevention strategies. Currently, few prevention 
options are available for women with germline BRCA1/2 muta-
tions. Women known to be at an increased genetic risk for devel-
oping OC, based on germline BRCA1/2 mutation carrier status, 
are offered risk-reducing salpingo–oophorectomy (RRSO), which 
reduces the risk of ovarian cancer by 71–96% (34–39). Surgery is 
usually performed after the completion of childbearing and while 
the woman is still pre-menopausal. Guidelines from the NCCN 
and the Society of Gynecologic Oncologists suggest that RRSO 
be completed by the age of 40 (19, 40); however, the majority of 
women who undergo RRSO do not do so by this age (41). This 
may be due to the potential side effects, such as premature surgi-
cal menopause (42), osteoporosis (43), cardiovascular disease 
(44, 45), cognitive impairments (46), symptoms of depression 
and anxiety (47), and consequences on quality of sleep, depres-
sion, and sexual dysfunction (48) associated with early RRSO. 
In light of these side effects – and the compelling evidence that 
high-grade serous epithelial ovarian cancer can be derived from 
the fallopian tube and not the ovary (49–53) – a recent commit-
tee opinion published by the American College of Obstetricians 
and Gynecologists outlines the opportunity for surgeon-led 
FiGURe 2 | Germline BRCA1/2 mutational frequencies worldwide – examples.
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discussions with patients regarding the potential benefits of the 
removal of the fallopian tubes during hysterectomy in women 
at population risk of ovarian cancer who are not having an 
oophorectomy (54). Young BRCA1/2 mutation carriers can be 
counseled for risk-reducing bilateral salpingectomy initially, with 
subsequent bilateral oophorectomy after childbearing, although 
additional randomized controlled trials are warranted to support 
the validity of this approach. Further studies of associated hyster-
ectomy are warranted in the population to provide appropriate 
family counseling guidance (55, 56). These discussions are impor-
tant as data from nine countries have shown that preventative 
practices in women with germline BRCA1/2 mutations are varied 
despite guidelines (57). The study of 2677 women harboring 
germline BRCA1/2 mutations, who were an average of 3.9 years 
following genetic testing, showed that only 57.2% had undergone 
prophylactic surgery. This reveals differing uptake of preventative 
options by their country of residence (57). It also highlights the 
lack of effective alternate strategies for individuals identified to be 
at high risk, often for years before clinical development of disease 
or risk reduction procedures like surgery can be offered.
GeRMLiNe BRCA1/2 TeSTiNG STRATeGY
The current germline BRCA1/2 testing strategy is mainly based 
on patients diagnosed with cancer. As previously discussed, as a 
minimum, all patients with HGSOC should be approached for 
BRCA1/2 testing as well as those patients diagnosed with non-
mucinous ovarian cancer (Figure 2). Furthermore, knowledge of 
germline BRCA1/2 status in women living with ovarian cancer 
directly impacts first-degree relatives (FDRs), who have a 50% 
probability of carrying the same mutation and are yet to be 
diagnosed, and therefore, could also benefit from risk-reducing 
prevention strategies (58).
While there has been much debate regarding the concept 
of population-based germline BRCA1/2 screening (59), this 
targeted approach within the Ashkenazi Jewish community 
has been shown to be more effective than family history-based 
testing and cost-effective. A Canadian-led study comparing the 
detection of BRCA1/2 mutation carriers through Jewish popu-
lation-based genetic testing versus clinic-based genetic testing 
found that more unaffected women with a BRCA1 or 2 mutation 
were identified as a result of a genetic testing program targeting 
all Jewish women (60). This evidence supports the provision of 
genetic testing to all Jewish women (60). Conducted between 
2008 and 2012, around 6179 Jewish women were tested through 
the population-based program, which identified 93 mutation 
carriers (92 unaffected with cancer) in comparison to 38 female 
carriers identified through 487 referrals to the genetics center 
(29 unaffected with cancer). Study findings showed that popu-
lation genetic testing does not contribute to increased genetic 
counseling time but in fact decreases the overall time required 
when utilizing a population-based approach. Of particular 
importance, the 38% of women identified as having a BRCA1/2 
mutation would have qualified for genetic testing but were either 
unaware of the recommendation or had not been referred by 
their health-care provider (60). Examining a similar approach, 
a randomized controlled trial of germline BRCA1/2 gene muta-
tion testing in Ashkenazi Jewish women that compared family 
based testing to population screening, successfully enrolled and 
randomized 1034 participants (691 women, 343 men), of which 
1017 were eligible for analysis. Similarly, findings showed that 
overall 56% of carriers did not fulfill clinical criteria for genetic 
FiGURe 3 | Location of common and founder BRCA1 mutations by country. Schematic of common and founder mutations by country modified from 
Janavicˇius (71) and Ramus and Gayther (72). Relative risk data taken from Rebbeck et al. (73).
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testing, and germline BRCA1/2 prevalence was 2.45%. The fact 
that more than half of participants did not fulfill testing criteria 
is in agreement with previous data (61, 62), in which carriers 
lacked a strong family history of cancer. Moreover, the study 
also provided evidence that population-based genetic testing of 
Ashkenazi Jewish women does not adversely affect short-term 
psychological or quality of life outcomes (63). Cost-effective 
analyses conducted in parallel to the above study show that 
even when incorporating BRCA1/2 prevalence in family history 
negative individuals and genetic counseling costs, this specific 
population-based screening for germline BRCA1/2 mutations 
is highly cost-effective compared to family history-based 
approaches in Ashkenazi Jewish women aged 30 years and older 
(15). Screening based on founder mutations is feasible if the 
type of mutation is well known and allows for population-based 
screening approaches, such as in the Ashkenazi Jewish popula-
tion, where two founder mutations in BRCA1 (185delAG and 
5382insC) and one in BRCA2 (6174delT) account for 98–99% of 
identified mutations (64–67). This population-based screening 
approach is cost-effective, as previously described, given that 
2.5% of this population carry one of these three mutations (64), 
and these mutations account for 40% of ovarian cancer (68, 69).
Worldwide, variation in the distribution of BRCA1 and BRCA2 
mutations is well recognized, and in certain countries and ethnic 
communities the germline BRCA1/2 mutation spectrum is lim-
ited to a few founder mutations (70). However, both the number 
and frequency of germline BRCA1 and BRCA2 mutations vary 
among populations (Figures 3 and 4) (71–73). Findings from an 
international observational study of 19,581 BRCA1 and 11,900 
BRCA2 carriers from 55 centers in 33 countries on 6 continents 
provide strong evidence that breast and ovarian cancer risks 
vary by type and location of BRCA1/2 mutation (73). As such, 
much research is moving toward characterizing the functional 
significance of specific mutations or mutation locations (74, 75).
Located on the long arm of chromosome 17, BRCA1 
(MIM#113705) comprises 22 coding exons spanning 80  kb 
of genomic DNA and has a 7.8-kb transcript coding for an 
1863-amino-acid protein (76). BRCA2 (MIM#600185) is located 
on chromosome 13 and comprises 26 coding exons spanning 
70  kb of genomic DNA and gives an 11.4-kb transcript that 
encodes a protein of 3418 amino acids (77). Multifunctional 
in nature, BRCA proteins play important control functions in 
homologous recombination, the DNA DSB repair pathway, and 
early cellular response to DNA damage. BRCA1 also has a tran-
scriptional activator or repressor function and possesses a central 
role in chromatin remodeling and centrosome regulation. BRCA1 
and BRCA2 appear to behave as tumor suppressor genes, and 
mutations in either of these genes have been found throughout 
the entire coding region and at splice sites (78). In light of the 
structural and interactive complexity of BRCA1/2, international 
collaborations will not only continue to improve our understand-
ing of BRCA1/2 mutations and how mutation type and location 
influence breast and ovarian cancer risks (Figures  3 and 4) 
(71–73) but also help devise novel, targeted testing panels that 
FiGURe 4 | Location of common and founder BRCA2 mutations by country. Schematic of common and founder mutations by country modified from 
Janavicˇius (71) and Ramus and Gayther (72). Relative risk data taken from Rebbeck et al. (73).
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can potentially support specific population-based genetic testing, 
similar to the Ashkenazi Jewish population.
TRANSLATiNG KNOwLeDGe iNTO 
PRACTiCe
To ensure successful uptake of germline BRCA1/2 testing or 
preventative strategies, wide community engagement and educa-
tion regarding ovarian cancer are imperative. Following Angelina 
Jolie’s announcement that she carried a genetic mutation that 
increased her odds of developing breast and ovarian cancer, 
referrals for genetic counseling and BRCA1/2 testing appeared 
to have increased the awareness of cancer, particularly for breast 
cancer (79–81). While celebrities can bring heightened awareness 
to health issues, there is a need for these messages to be accom-
panied by more purposeful communication efforts to assist the 
public in understanding and using the complex diagnostic and 
treatment information that these stories convey (82).
In a small US study, data show that despite a significant propor-
tion of primary care patients requiring genetic counseling, there is 
compelling evidence that few are actually receiving these services 
(23). Data from the same study also indicate that while overall 
perceived cancer risk was higher among women with familial 
cancer risk, 27% of women with familial breast/ovarian cancer 
felt their risk was “low” and 32% felt their risk was lower than 
average – highlighting the need for educational interventions for 
patients as well as providers (23). This highlights the importance 
of considering the potential psychological impacts that may be 
associated with BRCA1/2 testing over time. Employing qualitative 
interviews (N = 49) and reflective diaries, a study of 33 patients 
showed that the short-term impact of a positive BRCA1/2 test 
result differs prior to, immediately following, and up to 24 months 
after having received test results (83). Conducted from December 
2006 to March 2010, data show that while women with cancer ini-
tially undergo genetic testing for their children, on confirmation 
of a positive test, the focus temporarily shifts to decision-making 
around their personal health needs. In fact, the threat of further 
disease caused anxiety around nurturing children and personal 
survival, which remained unresolved until women underwent 
risk-reducing surgery and in many continued as cancer worry 
(83). Here, findings help to illustrate where additional support 
for women during the testing process may be most beneficial. 
The long-term effects of a positive BRCA1/2 test result are also 
of relevance. A prospective single US centre study evaluating the 
long-term psychosocial effects of BRCA1/2 testing in a cohort 
of 464 women who had undergone genetic testing found that at 
long-term follow up (median 5 years; range 3.4–9.1 years), when 
assessing cancer-specific and genetic testing distress, perceived 
stress, and perceived cancer risk, there is modest increased 
distress in BRCA1/2 carriers compared to those women who 
received uninformative or negative test results (84). Despite the 
modest increase in distress, the group found no evidence of clini-
cally significant dysfunction or impact of long-term psychological 
dysfunction due to testing (84). Data indicate that when patients 
receive counseling both before and after testing, they have more 
knowledge and experience less uncertainty and anxiety after learn-
ing the results of BRCA1/2 test. Although, patient experiences 
may vary with test results (85). Therefore, when taken together, 
it is imperative that appropriate multidisciplinary, supportive 
structures are in place that women eligible for testing can rely 
upon, leading up to and following a positive test result, including 
at the time of risk-reducing surgery and during surveillance.
Testing positive for a germline BRCA1/2 mutation goes 
beyond the patient herself potentially impacting her children 
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and other members of their family by allowing cascade testing 
to proceed, if warranted (86). Accurate communication of test 
results is therefore critical for subsequent members to be tested. 
Research suggests fractured information dissemination among 
families when a positive germline BRCA1/2 test is communicated. 
In a systematic review of 29 publications from 26 studies, family 
communication regarding genetic risk is described as a delibera-
tive process whereby the individual’s personal risk is determined, 
within the context of family dynamics, family vulnerability and 
receptivity is assessed, which mediates what information will 
be conveyed, and ultimately, the appropriate time to disclose 
information (87). Numerous studies provide complementary 
data illustrating that issues impacting the communication of test 
results within families includes an individual’s responsibility to 
inform, emotional and developmental readiness – such as when 
parents disclose BRCA1/2 results to children (88) – and again, 
communicating in the context of the existing family culture 
(89, 90). A retrospective study highlighted many errors in the 
transmission of DNA-test results in families from early stages of 
probands recalling information directly from genetic counselors, 
to the interpretation of information by family members (91). 
Therefore, support provided by genetic counselors could improve 
the overall process, not only during communication to family 
members but also during the education of physicians regarding 
family centered genetic testing for the physicians who may have 
referred the patient for testing (92).
BRCA1/2 MUTATiON iMPACTS MORe 
THAN OvARiAN CANCeR TReATMeNT 
AND PReveNTiON
While the most described cancers driven by germline mutations 
in BRCA1/2 have been breast and ovarian, there is also mounting 
evidence to support the role of germline BRCA1/2 mutations 
contributing to other solid tumors, such as in prostate (93) and 
pancreatic (94, 95) cancers. In a United Kingdom study, Kote-Jarai 
et  al. screened 1864 men with prostate cancer between 36 and 
88 years of age and following analysis of the BRCA2 gene, findings 
show that all carriers of truncating mutations developed prostate 
cancer at ≤65 years (93). In this study, the prevalence of BRCA2 
mutations was 1.27% (8/632) for cases diagnosed ≤55 years, 1.20% 
(19/1589) for cases diagnosed ≤65 years, and 0% (0/243) for cases 
diagnosed >65 years; p = 0.14 (81). It is estimated that germline 
mutations in the BRCA2 gene confer an ~8.6× increased risk of 
prostate cancer by 65 years of age, corresponding to an absolute 
risk of ~15% by age 65. A higher risk is perhaps conferred due to 
mutations in the BRCA2 ovarian cancer cluster region (OCCR) 
(96). Data suggest that routine testing of early onset prostate can-
cer cases for germline BRCA2 mutations would further help refine 
the prevalence of risk associated with BRCA2 mutations (93). A 
study examining other cancers in 268 BRCA1 and 222 BRCA2 
families in the United Kingdom from 1975 to 2005 using person-
years at risk analysis showed BRCA2 mutation increased risks for 
pancreatic cancers (RR 4.1, 95% CI 1.9–7.8) and uveal melanoma 
(RR 99.4 95% CI 11.1–359.8). Study data also showed possible 
novel associations with upper gastrointestinal malignancies and 
BRCA1 mutations, although this requires confirmation in future 
large prospective studies (96). Recently, a study provided evidence 
supporting current recommendations for hereditary breast and/or 
ovarian cancer screening of cancers other than breast and ovarian 
by the NCCN. In the study of 1072 patients who tested positive for 
a deleterious BRCA1/2 mutation, 1177 cancers comprising 30 dif-
ferent cancer types were detected (97). Findings show that while 
individuals harboring BRCA1 mutation did not have a significant 
increase in the development of cancers other than breast and 
ovarian, a trend in melanoma was observed. In addition, patients 
harboring a BRCA2 mutation had a significantly higher number 
of observed cases compared to expected cases for pancreatic 
cancer (SIR 21.7, 95% CI = 13.1–34.0; p < 0.001) in both men and 
women and prostate cancer in men (SIR 4.9, 95% CI = 2.0–10.1; 
p <  0.002) (97). Taken together, germline BRCA1/2 mutations 
bear significance in more than just breast and ovarian cancers. 
Future studies are warranted to provide evidence of access to 
BRCA1/2 testing and counseling for these cancers as well.
CONCLUSiON
Worldwide, give the high incidence of ovarian cancer, the oppor-
tunity to identify BRCA1/2 carriers at the time of their cancer 
diagnosis – and those at risk for developing disease – can impact 
therapeutic interventions. Therefore, it also provides compelling 
evidence to improve and standardize BRCA1/2 testing practices. 
This becomes further punctuated when the opportunity to 
prevent or diagnose disease early in FDRs is also considered. In 
appropriate settings, population-based testing may be effective in 
identifying individuals at risk, who, with current criteria, would 
otherwise be missed. Future research should strive to build novel, 
targeted testing panels that will facilitate treatment/prevention-
based decision-making. Therefore, it will be important to invest 
in resources and approaches that will change how ovarian cancer 
and other solid tumors with BRCA1/2 involvement are managed 
and prevented, to improve the current paradigm of care.
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